Device Helps Smokers Kick Cigarettes Without Drugs

Share Article

A North Carolina company has introduced new variants of its smoking cessation device that helps smokers quit smoking without the use of drugs. Brady Development, Inc., of Raleigh, NC, reports that smokers can curb the symptoms of withdrawal with gradual and structured weaning. The tool, called the 'Linkman', fits on the smoker's key chain, and it is used whenever the smoker desires a cigarette. The company reports that by using this 'habit reversal tool', a typical user can quit smoking much more easily without resorting to other drugs.

A North Carolina company has introduced new variations of a smoking cessation device that helps smokers quit smoking without the use of drugs. According to the U.S. Centers for Disease Control, if smokers do not come up with an effective action plan to quit smoking, their chance of success is just 1 in 20. This represents a 95% failure rate. Nearly half of all adult smokers are destined to smoke themselves to death, each an average of 15 years early.

They are dying not for lack of trying or wanting to quit. Rather, they deeply believe that they can figure out how to quit on their own, running out of time before getting it right.

For many smokers, quitting cold turkey is not possible. Nicotine withdrawal brings with it extreme frustration and irritability for a much longer period than the average would-be quitter expects. These extended side effects are strong enough to cause serious disruptions in lifestyle or even an undesirable change in personality. Accordingly, the 'quit smoking' industry has grown to a billion-dollar-a-year business, with products ranging from antidepressant pills to nicotine replacement therapy (NRT) products like patches or gum, to newer experimental drugs.

The stop smoking drug Chantix (Varenicline) has been shown to have a number of potential side effects including nausea, changes in dreaming, constipation, and vomiting and more serious side effects including depressed mood, agitation, and suicidal thoughts and behaviors.

Nicotine replacement therapy (NRT) is good for helping smokers to kick the physical habit, but for the more serious chemical component of the addiction, the addict is expected to wean himself off of the gum, lozenge, or patch. Because these do nothing to help smokers beat the chemical addiction, many would-be quitters find themselves stuck on the NRT products - or worse, bouncing back and forth between NRT and their original habits.

An alternative can be found in a class of products called smoking cessation devices, which use behavior modification strategies to enable people to wait longer and longer between cigarettes. The result is that smokers gradually wean themselves from cigarettes. And since they have more time to learn how to win the internal battle with addiction, the quitting is usually permanent.

In March of 2006, Brady Development, Inc., of Raleigh, NC received a United States Utility Patent (#7,015,796) for their Linkman Habit Reversal Tool. With this device, smokers can effectively wean themselves from a habit with less side effects. The battery-powered device is shaped like a small cigarette for a placebo effect, but is small enough to be worn as a pendant or carried on a key chain. It is discreet, attractive, and fun to use.

The three new variations of the Linkman each have different "quitting profiles" to gradually wean a smoking addiction down to approximately 1 cigarette per day within 1, 3, or 6 months. The company is so confident about the effectiveness of these products that they offer a 150% guarantee.

So, for smokers who can't seem to quit cold turkey and don't want to use yet more drugs to help them quit, there is an effective alternative, whatever the level of addiction.

Made in the U.S.A, the Linkman can only be purchased on the World Wide Web at http://www.linkman.com. Price: $99.95. For more information, contact Brady Development, Inc.; E-mail: steph @ linkman.com.

# # #

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Stephanie Lahousse, PhD